Biotechnology major Biocon on Monday said it has appointed Suresh Subramanian as the Head of the company's branded formulations (India) business.
"Suresh has over 30 years of experience in the pharmaceuticals market, having worked in India and Thailand for MNCs such as GlaxoSmithKline, Novartis, AstraZeneca and Pfizer. Over the years, he has played multiple leadership roles in Business Development, Marketing, Sales and Strategy," the company said in a statement.
Suresh has managed a wide portfolio spanning diverse therapy areas such as Neurosciences, Respiratory, Cardiology, Oncology, Critical Care, Gastro-Intestinal, Ophthalmology, Pain & Inflammation and Women's Health in the Indian market. He has also played a critical role in mapping the pharma opportunity in India as part of the Steering Committee for McKinsey's India Pharma 2020 report.
Biocon CMD Kiran Mazumdar-Shaw said: "Suresh has deep expertise in diverse therapy areas including Oncology, Cardiology and Critical Care and has a proven track record of delivering robust business growth. We are sure, under his leadership, our Branded Formulations business will evolve further and become a strong value builder for Biocon."
Biocon's Branded Formulations (India) business is a biologics-led, specialty pharma business focused on the chronic therapy areas of diabetes, cancer and autoimmune conditions.